Ginger Riley ~Eternal Optimist~ retweeted
Be sure to catch the next session of the NRG Protocol Support Committee's "Discuss With Us" series on Wednesday, November 18th - the topic will be: Making RECIST/iRECIST Real: Examples You Can Use. Visit ow.ly/Cno851008Vr to learn more and to register!
Ginger Riley ~Eternal Optimist~ retweeted
Whether you are new to NRG, transitioning into a new role, or taking on different clinical trials, the NRG Mentorship Program offers personalized support from experienced NRG members. Learn more ➡️nrgoncology.org/?post_type=n…
Ginger Riley ~Eternal Optimist~ retweeted
Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back after initial therapy. Learn more: bit.ly/ea3191-study #HeadAndNeckCancer #HNCA
Ginger Riley ~Eternal Optimist~ retweeted
What’s Next for NF1: Two approved treatments for plexiform neurofibromas, the first-ever NF1 platform trial launching in Europe, and 50 active CTF-funded research projects across the pipeline. Watch the webinar here: youtu.be/qb8hXw6iKdQ
#EndNF
Ginger Riley ~Eternal Optimist~ retweeted
.@MonikaJoshimd and @PGrivasMDPhD are leading #ClinicalTrial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced #UrothelialCancer. bit.ly/ea8231-study
Ginger Riley ~Eternal Optimist~ retweeted
NCI-supported researchers have developed an #AI tool called BRIDGE that can predict which breast cancers will fully respond to chemotherapy given before surgery. Read more: go.nih.gov/TdbXh2H
Ginger Riley ~Eternal Optimist~ retweeted
The usual treatment for #OlderAdults with early-stage #melanoma includes two surgeries. The EA6244 study asks: could one surgery + close monitoring be just as effective for some people? More info: bit.ly/ea6244-study cc: @YanaNajjarMD @JaniceM10
Ginger Riley ~Eternal Optimist~ retweeted
Inherited #BRCA1 and #BRCA2 mutations may affect how breast tumors evolve and respond to treatment, according to a study from MSK and collaborators involving genomic data from more than 5,800 patients.
MSK breast medical oncologist @PedramRazaviMD spoke with @TargetedOnc about the findings and how they could inform future treatment strategies. Learn more: bit.ly/4hMRBym
Ginger Riley ~Eternal Optimist~ retweeted
FC Cincinnati Game Notes for Friday's Leagues Cup Phase One match vs Pumas are now available: fccincy.com/4bxyO6x
Ginger Riley ~Eternal Optimist~ retweeted
The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: bit.ly/gable-trial
cc: @DukeRadiology, @glioblastf, @gbmfoundation
Ginger Riley ~Eternal Optimist~ retweeted
#FindingsFriday: Don’t miss the newest round-up of recently published findings from @eaonc #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/4pQOTde
Ginger Riley ~Eternal Optimist~ retweeted
👨⚕️The @theNCI has named Senthil K. Muthuswamy, PhD, (@3dorganoid) as Director of the Center for Cancer Research.
An internationally recognized cancer biologist, he is known for pioneering 3D organoid culture methods and translational cancer research.
🔗 ascopost.com/news/july-2026/…
Ginger Riley ~Eternal Optimist~ retweeted
Baklava, #ALL advancements, #clinicaltrials, community outreach and more: Catch the latest episode of the Oncology Insights podcast with Fred Hutch's @PGrivasMDPhD and #leukemia physician-researcher Dr. Ryan Cassaday. bit.ly/4hesXqn
Ginger Riley ~Eternal Optimist~ retweeted
🧬 The phase 3️⃣ BRUIN CLL-322 trial found fixed-duration pirtobrutinib + venetoclax-rituximab significantly improved PFS vs venetoclax-rituximab alone in previously treated CLL/SLL.
➡️"potential new SOC" from @DrMDavids et al in @TheLancet | #EHA2026
🔗 ascopost.com/news/july-2026/…
Ginger Riley ~Eternal Optimist~ retweeted
EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: bit.ly/ea8192-trial #blcsm
Ginger Riley ~Eternal Optimist~ retweeted
Cooperative group research helps answer questions that matter to patients. The ENDURANCE trial provides evidence on the optimal duration of lenalidomide maintenance, & a new @NEJM editorial discusses its implications for #MultipleMyeloma care. More: bit.ly/4yVRsPo
Ginger Riley ~Eternal Optimist~ retweeted
#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more: bit.ly/EA4231 cc: @LLSusa, @lymphomahub
Ginger Riley ~Eternal Optimist~ retweeted
💉High-dose chemotherapy then autologous stem cell transplantation improved OS vs nonmyeloablative consolidation in patients with primary CNS lymphoma who responded to MATRix induction.
➡️ Results from phase III MATRix/IELSG43 trial
🔹 Gerald Illerhaus, MD
ascopost.com/news/july-2026/…
Ginger Riley ~Eternal Optimist~ retweeted
🌐The @WHO has released the first global 5-year #breastcancer survival estimates to help countries monitor progress toward reducing breast cancer mortality, reinforceing the importance of early diagnosis, timely treatment, and access to care worldwide.
🔗 ascopost.com/news/july-2026/…
Ginger Riley ~Eternal Optimist~ retweeted
On #WorldLungCancerDay, we recognize the patients, caregivers & researchers working to improve outcomes for people with #lungcancer. Thru clinical trials & collaborative research, we're advancing new approaches to prevention & treatment to help shape the future of cancer care.























